Will AstraZeneca shares move higher after China Covid-19 vaccine deal?
The British-Swedish drug maker has seen its share price perform well in 2020. But will the company’s stock push even higher after securing the first coronavirus vaccine deal with China?
AstraZeneca has trended lower this week, returning to levels seen throughout June after the stock rallied to an all-time high of £93.20 per share in mid-July. However, the drug maker is well-positioned to see its shares soar once again after signing the first Covid-19 vaccine deal with China.
The deal will see China-based Shenzhen Kangtai Biological Products produce AstraZeneca’s potential Covid-19 vaccine in mainland China – securing the drug maker's pole position in the global race to deliver a cure for the coronavirus pandemic.
AstraZeneca is trading at £83.16 per share at the time of publication, with the stock up 9% year-to-date.
AstraZeneca: outlook for 2020
AstraZeneca CEO Pascal Soriot praised his employees for the company’s strong performance in its half-year (H1) results at the end of July, with the business delivering further revenue growth that has helped improve profitability and cash generation.
The drug maker has performed particularly well in emerging markets and has seen success with its newly developed medicines, along with the company becoming a leader in the fight against Covid-19.
‘Looking ahead, while we continue to anticipate variations in quarterly performance, the continuation of our strategy makes us confident about the future,’ Soriot said.
‘We are retaining our full-year guidance that is underpinned by the focus on commercial execution and an exciting pipeline of new medicines,’ he added.
Total revenue is expected to increase by a high single-digit to a low double-digit percentage in 2020 and core earnings per share is expected to increase by a mid- to high-teens percentage, according to AstraZeneca’s own guidance which has been left unchanged.
AstraZeneca-Oxford University Covid-19 vaccine produces immune response
AstraZeneca shares are likely to get a boost after its partnership with Oxford University has shown promising results from early stage trials for a potential coronavirus vaccine.
In fact, a new study published earlier this month in the scientific journal, The Lancet, showed that a team of scientists from Oxford University’s Jenner Institute and Oxford Vaccine Group have created a Covid-19 vaccine that induces a strong immune response to the virus.
'We are encouraged by the Phase I/II interim data showing AZD1222 was capable of generating a rapid antibody and T-cell response against SARS-CoV-2,’ Mene Pangalos, executive vice-president of BioPharmaceuticals R&D at AstraZeneca, said.
‘While there is more work to be done, today’s data increases our confidence that the vaccine will work and allows us to continue our plans to manufacture the vaccine at scale for broad and equitable access around the world,’ he added.
How to trade stocks with IG
Looking to trade AstraZeneca and other stocks? Open a live or demo account with IG and buy (long) or sell (short) shares using derivatives like CFDs in a few easy steps:
- Create an IG trading account or log in to your existing account
- Enter ‘AstraZeneca’ in the search bar and select it
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Act on stock opportunities today
Go long or short on thousands of international stocks with CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
